NASDAQ · KYTX
Healthcare · Biotechnology
$5.16
Up+$0.02 (+0.39%)
Updated Nov 4, 2026, 8:31 PM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · KYTX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
KYTX closed at $5.16 after 21 trading sessions, down 16.23% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $5.28 | $5.48 | $5.12 | $5.16 | 705.26K |
| Nov 2, 2026 | $5.70 | $5.84 | $5.0925 | $5.22 | 822.31K |
| Oct 30, 2026 | $5.74 | $5.87 | $5.55 | $5.67 | 640.17K |
| Oct 29, 2026 | $5.91 | $6.12 | $5.83 | $5.85 | 854.64K |
| Oct 28, 2026 | $5.58 | $5.935 | $5.56 | $5.89 | 995.41K |
| Oct 27, 2026 | $5.24 | $5.67 | $5.16 | $5.63 | 916.66K |
| Oct 26, 2026 | $5.35 | $5.41 | $5.18 | $5.27 | 810.11K |
| Oct 23, 2026 | $5.68 | $5.68 | $5.36 | $5.39 | 827.75K |
| Oct 22, 2026 | $5.825 | $5.985 | $5.67 | $5.73 | 519.39K |
| Oct 21, 2026 | $6.15 | $6.30 | $5.80 | $5.84 | 829.52K |
| Oct 20, 2026 | $5.83 | $6.20 | $5.80 | $6.04 | 766.31K |
| Oct 19, 2026 | $5.71 | $5.94 | $5.67 | $5.83 | 837.71K |
| Oct 16, 2026 | $5.94 | $6.05 | $5.64 | $5.67 | 726.28K |
| Oct 15, 2026 | $5.67 | $6.02 | $5.67 | $5.97 | 779.43K |
| Oct 14, 2026 | $5.76 | $5.845 | $5.61 | $5.685 | 1.28M |
| Oct 13, 2026 | $6.17 | $6.17 | $5.755 | $5.77 | 1.25M |
| Oct 12, 2026 | $6.34 | $6.46 | $6.19 | $6.21 | 417.11K |
| Oct 9, 2026 | $6.20 | $6.58 | $6.175 | $6.39 | 876.45K |
| Oct 8, 2026 | $6.06 | $6.2162 | $5.9602 | $6.18 | 1.32M |
| Oct 7, 2026 | $6.12 | $6.31 | $6.02 | $6.17 | 650.55K |
| Oct 6, 2026 | $6.38 | $6.45 | $6.13 | $6.16 | 739.52K |
The latest Smart Investors Daily articles mentioning KYTX.
Company
Market Activity
Research & News
KYTX research
Company profile and research snapshot.
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 3, 2026 | HC Wainwright & Co. | Buy | — |
| May 15, 2026 | HC Wainwright & Co. | Buy | — |
| May 13, 2026 | JP Morgan | Overweight | — |
| Apr 23, 2026 | HC Wainwright & Co. | Buy | — |
| Dec 16, 2025 | Wells Fargo | Overweight | — |
No generated briefing is available yet.
SeekingAlpha · Oct 28, 2026
Kyverna Therapeutics advances Miv-cel for autoimmune diseases, but valuation, launch, and funding risks remain. Click here to read this analysis on KYTX.
Benzinga · Oct 23, 2026
Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced updated data from a Phase 1
Yahoo · Oct 21, 2026
Miv-cel reversed disability and achieved durable efficacy across all primary and secondary endpoints through one year, with nearly all patients remaining off chronic immunotherapies Deep B-cell depletion demonstrated with a single dose supports the potential for broad immune reset enabled by miv-cel's unique construct Consistent, well-tolerated safety profile with no high-grade CRS or ICANS, and no cases of IEC-HS in one-year follow-up Data further strengthens SPS BLA package and supports potent
Benzinga · Oct 21, 2026
Miv-cel reversed disability and achieved durable efficacy across all primary and secondary endpoints through one year, with nearly all patients remaining off chronic immunotherapies Deep B-cell depletion demonstrated
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KYTX.
